ClearPoint Neuro, Inc.
CLPTHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, ClearPoint Neuro, Inc. (CLPT) is listed under Medical Devices. Valued at $278.8M, CLPT is a micro-cap name in its sector. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Market Cap
$278.8M
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-7.65
EPS (TTM)
$-1.18
EPS (Fwd)
$-1.20
ROE
-226.5%
ROA
-24.4%
Cash
$29.4M
Total Debt
$63.9M
Free CF
-$14.1M
52W Change
-63.1%
Annual Financials
Cash vs Debt
Where CLPT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CLPT finished 30.27% below its 150-day moving average ($13.15) and 30.53% below its 200-day moving average ($13.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLPT overbought or oversold?
At the October 20, 2026 close, CLPT's RSI(14) was 27.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $29.4M in cash, though total debt stands at $63.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$14.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -226.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $20.6M (2022) to $37.0M (2025), reflecting a 80% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLPT.